News
Public · Published
Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
Avacta Therapeutics announced updated Phase 1a/1b trial data showing faridoxorubicin (AVA6000) produced a median progression-free survival of 11.4 months in 32 patients with salivary gland cancer, compared with historical benchmarks of 6 to 6.7 months, and meaningful tumor shrinkage in most patients.
Published:
Updated:
What happened
Avacta Therapeutics announced updated Phase 1a/1b trial data showing faridoxorubicin (AVA6000) produced a median progression-free survival of 11.4 months in 32 patients with salivary gland cancer, compared with historical benchmarks of 6 to 6.7 months, and meaningful tumor shrinkage in most patients.
Confirmed
Global impact / market context
Progression-free survival is the time a patient lives without the cancer getting worse, so a near doubling versus older benchmarks could make this drug more competitive. That matters for Avacta's future trial plans, partnership appeal, and potential revenue if approved.
Analyst inference
Salivary gland cancer is a small patient group, so commercial interest depends on how regulators and partners value the survival gain. Investors may compare this result with other treatments, while the company's cash needs and trial costs will shape how far this data can be developed.
Analyst inference
What to watch
- The company reported sustained FAP expression and continued doxorubicin release beyond 10 cycles of therapy, based on FAPI-PET imaging and pharmacokinetic data in multiple patients. Confirmed
- Watch for details on the next trial stage, including whether Avacta proposes a larger study in salivary gland cancer and what timeline and budget it sets for that study. Proposed
- Watch whether the 95% confidence interval, which ranged from 7 months to not reached, tightens as more patients are followed and whether tumor shrinkage translates into longer overall survival. Analyst inference